Drug Eluting stent
- UID
- IMP/MD/2019/000050_fa2d22a986c236d5da466b1e8d914037_dca4407dba914ae3ec5b7fe09e8fd0e3
- Device class
- Class D
- Brand name
- Onyx TruCor Zotarolimus-Eluting Coronary Stent System
- License holder
- India Medtronic Private Limited
- Approving authority
- CDSCO
- Product information
- The Endeavor Resolute Zotarolimus Eluting Coronary Stent system is intended for use in patients eligible for Percutaneous Transluminal Coronary Angioplasty (Onyx TruCor Zotarolimus-Eluting Coronary Stent System) with a reference vessel diameter of 2.25 mm to 4.0 mm. Endeavor Resolute stent is intended to improve coronary luminal diameters as an adjunct to coronary interventions and reduce restenosis. The stents are intended as permanently implanted devices.
Drug Eluting stent is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/MD/2019/000050_fa2d22a986c236d5da466b1e8d914037_dca4407dba914ae3ec5b7fe09e8fd0e3. This device is marketed under the brand name Onyx TruCor Zotarolimus-Eluting Coronary Stent System. The license holder is India Medtronic Private Limited, and it is classified as Device Class Class D. The approving authority is CDSCO.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.